Literature DB >> 22409666

Modern phenotypic drug discovery is a viable, neoclassic pharma strategy.

Jonathan A Lee1, Mark T Uhlik, Christopher M Moxham, Dirk Tomandl, Daniel J Sall.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22409666     DOI： 10.1021/jm201649s

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  44 in total

Review 1.  Applications of chemogenomic library screening in drug discovery.

Authors:  Lyn H Jones; Mark E Bunnage
Journal:  Nat Rev Drug Discov       Date:  2017-01-20       Impact factor: 84.694

Review 2.  The discovery of first-in-class drugs: origins and evolution.

Authors:  Jörg Eder; Richard Sedrani; Christian Wiesmann
Journal:  Nat Rev Drug Discov       Date:  2014-07-18       Impact factor: 84.694

Review 3.  Phenotypic screening in cancer drug discovery - past, present and future.

Authors:  John G Moffat; Joachim Rudolph; David Bailey
Journal:  Nat Rev Drug Discov       Date:  2014-07-18       Impact factor: 84.694

4.  Comparative Proteomics of Dying and Surviving Cancer Cells Improves the Identification of Drug Targets and Sheds Light on Cell Life/Death Decisions.

Authors:  Amir Ata Saei; Pierre Sabatier; Ülkü Güler Tokat; Alexey Chernobrovkin; Mohammad Pirmoradian; Roman A Zubarev
Journal:  Mol Cell Proteomics       Date:  2018-03-23       Impact factor: 5.911

5.  Zebrafish Models of Kidney Damage and Repair.

Authors:  Maria Cecilia Cirio; Mark P de Caestecker; Neil A Hukriede
Journal:  Curr Pathobiol Rep       Date:  2015-04-11

6.  Development of high-content assays for kidney progenitor cell expansion in transgenic zebrafish.

Authors:  Subramaniam Sanker; Maria Cecilia Cirio; Laura L Vollmer; Natasha D Goldberg; Lee A McDermott; Neil A Hukriede; Andreas Vogt
Journal:  J Biomol Screen       Date:  2013-07-05

7.  Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society.

Authors:  Rehan Akbani; Karl-Friedrich Becker; Neil Carragher; Ted Goldstein; Leanne de Koning; Ulrike Korf; Lance Liotta; Gordon B Mills; Satoshi S Nishizuka; Michael Pawlak; Emanuel F Petricoin; Harvey B Pollard; Bryan Serrels; Jingchun Zhu
Journal:  Mol Cell Proteomics       Date:  2014-04-28       Impact factor: 5.911

8.  Comparison of methods for image-based profiling of cellular morphological responses to small-molecule treatment.

Authors:  Vebjorn Ljosa; Peter D Caie; Rob Ter Horst; Katherine L Sokolnicki; Emma L Jenkins; Sandeep Daya; Mark E Roberts; Thouis R Jones; Shantanu Singh; Auguste Genovesio; Paul A Clemons; Neil O Carragher; Anne E Carpenter
Journal:  J Biomol Screen       Date:  2013-09-17

9.  Structure-activity studies of divin: an inhibitor of bacterial cell division.

Authors:  Maoquan Zhou; Ye-Jin Eun; Ilia A Guzei; Douglas B Weibel
Journal:  ACS Med Chem Lett       Date:  2013-09-12       Impact factor: 4.345

10.  Phenotypic profiling of Raf inhibitors and mitochondrial toxicity in 3D tissue using biodynamic imaging.

Authors:  Ran An; Dan Merrill; Larisa Avramova; Jennifer Sturgis; Maria Tsiper; J Paul Robinson; John Turek; David D Nolte
Journal:  J Biomol Screen       Date:  2013-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.